Shares of Albany Molecular Research Inc. (NASDAQ:AMRI) were up 4.6% during trading on Tuesday . The stock traded as high as $15.79 and last traded at $15.76, with a volume of 231,728 shares trading hands. The stock had previously closed at $15.06.

Separately, Morgan Stanley restated a “buy” rating and set a $17.00 price objective on shares of Albany Molecular Research in a research report on Friday, August 5th.

The stock’s market cap is $542.80 million. The company’s 50 day moving average is $14.86 and its 200 day moving average is $14.60.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/albany-molecular-research-inc-amri-trading-up-4-6.html

Albany Molecular Research (NASDAQ:AMRI) last released its earnings results on Thursday, August 4th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.04. The company had revenue of $116.50 million for the quarter, compared to the consensus estimate of $123.10 million. Albany Molecular Research had a negative net margin of 7.37% and a positive return on equity of 3.17%. Analysts anticipate that Albany Molecular Research Inc. will post $1.09 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in AMRI. BNP Paribas Arbitrage SA increased its stake in Albany Molecular Research by 116.1% in the second quarter. BNP Paribas Arbitrage SA now owns 8,329 shares of the company’s stock valued at $112,000 after buying an additional 4,475 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Albany Molecular Research during the second quarter valued at approximately $145,000. Louisiana State Employees Retirement System increased its stake in Albany Molecular Research by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 12,000 shares of the company’s stock valued at $161,000 after buying an additional 100 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Albany Molecular Research by 1.1% in the second quarter. State Board of Administration of Florida Retirement System now owns 12,318 shares of the company’s stock valued at $166,000 after buying an additional 140 shares during the period. Finally, BlackRock Advisors LLC increased its stake in Albany Molecular Research by 3.1% in the second quarter. BlackRock Advisors LLC now owns 12,382 shares of the company’s stock valued at $166,000 after buying an additional 374 shares during the period. 71.39% of the stock is currently owned by institutional investors.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

5 Day Chart for NASDAQ:AMRI

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.